Copertina

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ting Zhang, Sicheng Du, Ying Zhang, Rongrui Liu, Juan Li, Chuanhua Zhao, Jianming Xu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Cancer Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
di: Chengxiang Guo, et al.
Pubblicazione: (2025)

Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
di: Tasuku Nakabori, et al.
Pubblicazione: (2026)

Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study
di: Amanda Nizam, et al.
Pubblicazione: (2025)

A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab
di: Atsuto Mouri, et al.
Pubblicazione: (2025)

A Real‐World Experience of Prognostic Factors of Survival Outcomes in a Taiwanese Population With Unresectable Hepatocellular Carcinoma Treated With First‐Line Lenvatinib
di: Shou‐Wu Lee, et al.
Pubblicazione: (2026)

Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study
di: Bei Xu, et al.
Pubblicazione: (2026)

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
di: Atsushi Naganuma, et al.
Pubblicazione: (2025)

ACSL3 Promotes Hepatocellular Carcinoma Tumorigenesis and Correlates With JAK – STAT3 Signaling
di: Melika Amelimojarad, et al.
Pubblicazione: (2026)

Preoperative Serum Glycan Levels Reflect Progression of Patients With Hepatocellular Carcinoma
di: Sheng‐Sheng Liu, et al.
Pubblicazione: (2024)

An Overview of In Vitro Models of Alcohol‐Related Hepatocellular Carcinoma
di: Anoïsia Courtois, et al.
Pubblicazione: (2025)

The Treatment of Primary Lymphoepithelioma‐Like Carcinoma in the Head and Neck and Nasopharyngeal Carcinoma
di: Qiaohong Lin, et al.
Pubblicazione: (2024)

Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib
di: E. Agostani, et al.
Pubblicazione: (2025)

Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy
di: Chihiro Miwa, et al.
Pubblicazione: (2025)

Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment
di: Xiuping Lai, et al.
Pubblicazione: (2024)

Survival Benefit and Safety of Anatomic Resection in Cirrhotic Hepatocellular Carcinoma: Propensity‐Matched Analysis of 1699 Patients
di: Ao Du, et al.
Pubblicazione: (2026)

Gut Microbiota as Mediator and Moderator Between Hepatitis B Virus and Hepatocellular Carcinoma: A Prospective Study
di: Bingren Hu, et al.
Pubblicazione: (2024)

RIOK1: A Novel Oncogenic Driver in Hepatocellular Carcinoma
di: Chunyan Ruan, et al.
Pubblicazione: (2025)

JMT103 versus Non‐Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score‐Matched Comparison
di: Hairong Xu, et al.
Pubblicazione: (2025)

An XGBoost ‐Based Multicenter Model for Predicting HBV ‐Related Hepatocellular Carcinoma: Development and Validation
di: Yong Lin, et al.
Pubblicazione: (2026)

Real‐World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of Postmarketing Surveillance
di: Eiji Kikuchi, et al.
Pubblicazione: (2025)

Correction to “Highly Expressed Carbohydrate Sulfotransferase 11 Correlates With Unfavorable Prognosis and Immune Evasion of Hepatocellular Carcinoma”
Pubblicazione: (2025)

Machine Learning‐Based Model for Predicting Recurrence‐Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients
di: Ningning Lu, et al.
Pubblicazione: (2025)

Safety and Efficacy of Salvage Treatment for Recurrent Nasopharyngeal Carcinoma: A Single‐Center Retrospective Study Over 10 Years
di: Yanrong Luo, et al.
Pubblicazione: (2026)

Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy
di: Kenji Imai, et al.
Pubblicazione: (2026)

Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
di: Pooja Gokhale, et al.
Pubblicazione: (2026)

A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database
di: Boyi Liu, et al.
Pubblicazione: (2026)

Prognostic Role of Hemoglobin Combined With Geriatric Nutritional Risk Index in Patients With Vater Ampulla Carcinoma Undergoing Pancreaticoduodenectomy
di: Jieping Ying, et al.
Pubblicazione: (2024)

Assessing the Causal Effect of Circulating Protein‐To‐Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma
di: Qiuyuan Yue, et al.
Pubblicazione: (2025)

The Prognosis of Urothelial Carcinoma Between Kidney Transplantation Recipients and Normal Patients: A Propensity Score‐Matched Study
di: Wu Taihao, et al.
Pubblicazione: (2025)

Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation
di: Kunmin Xiao, et al.
Pubblicazione: (2025)

Extracellular Volume Fraction Combined With Pathological Features of α‐SMA and FAP for Predicting the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma After Surgery and Evaluating the Efficacy of Chemotherapy
di: Liqiang Liu, et al.
Pubblicazione: (2025)

Oncological Outcomes Following Different TACE ‐Based Conversion Therapies for Intermediate‐Advanced Hepatocellular Carcinoma
di: Hongwei Xu, et al.
Pubblicazione: (2026)

Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset
di: Wei Wang, et al.
Pubblicazione: (2026)

Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post‐Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy
di: Masayoshi Nagata, et al.
Pubblicazione: (2025)

A Novel MPT ‐Driven Necrosis‐Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids
di: Yang Liu, et al.
Pubblicazione: (2025)

Anti‐Angiogenic Agents for Advanced Hepatocellular Carcinoma Induce Liver Atrophy
di: Taijiro Wake, et al.
Pubblicazione: (2025)

Bi‐Regional Machine Learning Radiomics Based on CT Noninvasively Predicts LOX Expression Level and Overall Survival in Hepatocellular Carcinoma
di: Kexin Gao, et al.
Pubblicazione: (2025)

The Role of Chemokine (C‐C Motif) Ligand 7 (CCL7) in Hepatocellular Carcinoma: Expression, Function, and Mechanisms
di: Yangkun Luo, et al.
Pubblicazione: (2025)

Transarterial Infusion Chemotherapy and Embolization for Patients With Unresectable Advanced Cancer of Stomach or Gastroesophageal Junction: A Retrospective Study
di: Lingqiang Min, et al.
Pubblicazione: (2024)

Evaluation of Efficacy of Neoadjuvant Immunochemotherapy for Cervical Metastatic Squamous Cell Carcinoma of Unknown Primary
di: Xianlu Gao, et al.
Pubblicazione: (2025)